Gilead's Yeztugo generated $232M in Q2, beating estimates, while the company's overall HIV PrEP franchise topped $1B.
Gilead said its twice-yearly HIV prevention shot Yeztugo generated $232 million in sales in the second quarter, topping Wall Street estimates of $221 million.
The …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability
Gilead Slumps As Long-Term Uncertainty Clouds Big HIV Beat
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year
Three biotechs with three news updates
HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts
The HIV shot that could change medicine is facing its biggest test: Getting to patients
